Abbott, Reckitt face trial over premature baby formula amid alarm from doctors
Corrects title of Jonathan Davis in paragraph 9, to Chief of Newborn Medicine at Tufts Medical Center
Doctors fear losing access to essential formulas for premature babies
Plaintiffs argue companies failed to warn about NEC risk from cow's milk-based formula
By Brendan Pierson
Sept 30 (Reuters) -A Missouri mother and her lawyers this week will aim to convince a jury that Abbott ABT.N, Reckitt's RKT.L Mead Johnson and St. Louis Children's Hospital are responsible for a severe intestinal illness that she says her premature son got from the companies' formulas after he was born at the hospital.
The closely watched trial in St. Louis, Missouri state court, which begins with jury selection on Monday, is part of sprawling litigation that has already resulted in verdicts of $60 million against Reckitt and $495 million against Abbott. Close to 1,000 similar cases are still pending nationwide.
Plaintiffs argue that giving cow's milk-based formula to premature babies - especially the smallest ones, born weighing less than about 1,500 grams or about three pounds - greatly increases their risk of developing necrotizing enterocolitis (NEC). That condition has an estimated fatality rate of more than 20%. They also say the companies had a legal responsibility to warn about that risk, but failed to do so.
Both companies said in statements that the lawsuit's claims are not supported by evidence and that their products are essential for premature babies.
St. Louis Children's did not respond to a request for comment on the litigation.
Large verdicts in the two cases that have so far gone to trial have raised alarm among doctors who fear losing access to products they depend on to feed babies.
Abbott and Reckitt are the only companies selling the formulas at issue, which are specialized products used in newborn intensive care units. In a July investor call, Abbott CEO Robert Ford suggested that they might become unavailable because of the litigation. Reckitt also said it was considering "strategic options" for its formula division.
The products for premature babies are not big sellers, bringing Abbott only about $9 million and Reckitt less than $1 million annually, according to company spokespersons.
"I would say there's a genuine panic," said Jonathan Davis, who is Chief of Newborn Medicine at Tufts Medical Center in Boston.
Doctors say the benefits of breast milk for premature babies on a wide range of measures – including lower rates of NEC – have been known for years, and are reflected in hospital feeding practices. But, they say, formula remains vital to feed babies when the mother's or donated breast milk is unavailable or insufficient.
"I would love if every mother could give me breast milk. They can't," said Jill Maron, chief of pediatrics at Women & Infants Hospital in Providence, Rhode Island. "If I don't have access to these products, babies will die."
'MESSAGE OF FEAR'
Tor Hoerman, a lawyer who represents the plaintiff who won the $495 million verdict and others, said doctors are responding to a "message of fear" pushed by the manufacturers, who were unnecessarily suggesting that the products might be withdrawn.
"Nobody is requesting that the product be pulled from the market," Hoerman said. Instead, he said, the companies "could put a simple warning about risk" on the formulas' labels.
At the upcoming trial, plaintiff Elizabeth Whitfield will urge the jury to find that the companies and the hospital were negligent under Missouri law. She says her son, who was born at less than 28 weeks in August 2017, developed NEC the following month as a result of being fed formula and required surgery to remove part of his intestine.
Whitfield's son, like many NEC survivors who have surgery, "continues to suffer from permanent and severe injuries," according to the lawsuit.
The lawsuit and others like it are separate from cases over allegedly contaminated formula from an Abbott factory in Michigan. There are no allegations that the premature baby formula was contaminated.
The science around NEC, breast milk and formula feeding remains unsettled.
A recent report from a U.S. National Institutes of Health working group said that current evidence "supports the hypothesis that it is the absence of human milk – rather than the exposure to formula – that is associated with an increase in the risk of NEC."
The manufacturers say that a label warning that formula can cause NEC would be unsupported. And because doctors are already aware of the research, they say, a label would not change anything.
Several neonatologists interviewed by Reuters said they worried that a warning label could make parents believe formula was unsafe even when it was the best available option.
The NEC Society, a patient-led organization devoted to fighting the disease, has said that formula is sometimes necessary and that lawsuits are not part of its strategy.
"What I would love for everyone to focus on is how we increase equitable access to mother's milk and pasteurized donor milk," said NEC Society Director Jennifer Canvasser, who founded the organization after losing her own son to the disease.
Reporting By Brendan Pierson in New York, Editing by Alexia Garamfalvi and Anna Driver
Aloqador aktivlar
Eng oxirgi yangiliklar
Javobgarlikdan voz kechish: XM Group korxonalari har biri faqat ijro xizmatlarini koʻrsatadi va onlayn savdo platformamizdan foydalanish huquqini beradi, bu odamga veb-saytda yoki veb-sayt orqali mavjud boʻlgan kontentni koʻrish va/yoki undan foydalanishga ruxsat beradi hamda uni oʻzgartirishga moʻljallanmagan va uni oʻzgartirmaydi yoki kengaytirmaydi. Bunday kirish va foydalanish huquqi doimo quyidagilarga boʻysunadi: (i) Shartlar va qoidalar; (ii) Risklar haqida ogohlantirish; va (iii) Javobgarlikni toʻliq rad etish. Shuning uchun bunday kontent umumiy maʼlumot sifatida taqdim etiladi. Xususan, shuni esda tutingki, bizning onlayn savdo platformamiz mazmuni moliyaviy bozorlarda biror bitimni amalga oshirishga oid maslahat yoki taklif emas. Har qanday moliyaviy bozorda savdo qilish sizning kapitalingiz uchun jiddiy risk darajasini oʻz ichiga oladi.
Onlayn savdo platformamizda chop etilgan barcha materiallar faqat taʼlim/axborot maqsadlari uchun moʻljallangan va unda moliyaviy, investitsiya soligʻi yoki savdo maslahatlari va tavsiyalar; yoki bizning savdo narxlarimizning qaydlari; yoki har qanday moliyaviy vositalar bilan bitim tuzish maslahati yoki taklifi; yoki sizga kerak boʻlmagan moliyaviy reklama aksiyalari hisoblanmaydi
Har qanday uchinchi tomon kontenti, shuningdek XM tomonidan tayyorlangan kontent, masalan: fikrlar, yangiliklar, tadqiqotlar, tahlillar, narxlar va boshqa maʼlumotlar yoki bu veb-saytda joylashgan uchinchi tomon saytlariga havolalar umumiy bozor sharhi sifatida "boricha" taqdim etiladi va investitsiya maslahatini tashkil etmaydi. Har qanday kontent investitsiya tadqiqoti sifatida talqin qilinsa, siz bunday kontentni investitsiya tadqiqotlarining mustaqilligini ragʻbatlantirish uchun moʻljallangan qonun talablariga muvofiq moʻljallanmagan va tayyorlanmaganligini eʼtiborga olishingiz va qabul qilishingiz kerak, shuning uchun unga tegishli qonunlar va qoidalarga muvofiq marketing kommunikatsiyasi sifatida qaraladi. Mustaqil boʻlmagan investitsiya tadqiqoti va yuqoridagi maʼlumotlarga oid risk haqida ogohlantirishimizni oʻqib chiqqaningizga va tushunganingizga ishonch hosil qiling, unga bu yerdan kirish mumkin.
